Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - IL
$ 5.6367
-0.235 %
$ 7.18 M
Market Cap
-0.02
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart RDHL
FINANCIALS
Balance Sheet
RedHill Biopharma Ltd.
| Current Assets | 16.1 M |
| Cash & Short-Term Investments | 6.36 M |
| Receivables | 3.29 M |
| Other Current Assets | 6.5 M |
| Non-Current Assets | 6.91 M |
| Long-Term Investments | 147 K |
| PP&E | 1.18 M |
| Other Non-Current Assets | 5.58 M |
| Current Liabilities | 19.2 M |
| Accounts Payable | 3.28 M |
| Short-Term Debt | 718 K |
| Other Current Liabilities | 15.2 M |
| Non-Current Liabilities | 1.74 M |
| Long-Term Debt | 455 K |
| Other Non-Current Liabilities | 1.28 M |
EFFICIENCY
Earnings Waterfall
RedHill Biopharma Ltd.
| Revenue | 6.51 M |
| Cost Of Revenue | 3.46 M |
| Gross Profit | 3.05 M |
| Operating Expenses | -9.56 M |
| Operating Income | 12.6 M |
| Other Expenses | -11.3 M |
| Net Income | 23.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
RedHill Biopharma Ltd.
| Net Income | 23.9 M |
| Depreciation & Amortization | 1.99 M |
| Capital Expenditures | -11 K |
| Stock-Based Compensation | 1.65 M |
| Change in Working Capital | -15.6 M |
| Others | -98.2 M |
| Free Cash Flow | -35.8 M |
Wall Street Analysts Price Targets
RedHill Biopharma Ltd.
RDHL has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
RDHL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
RedHill Biopharma Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident There are currently no known approved therapies for gastrointestinal acute radiation syndrome (GI-ARS) Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract, further confirm opaganib's protective activity Discussions now ongoing with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID), which leads the RNCP, regarding plans for the next phase of development along the U.S. Food and Drug Administration's (FDA) Animal Rule pathway to approval TEL AVIV, Israel and RALEIGH, N.C. , Dec. 10, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
prnewswire.com
- 1 month ago
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the agreements TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
prnewswire.com
- 1 month ago
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day" -- Based on reviews, feedback, and discussion, the judges selected for presentation those therapeutics that demonstrated capability in the prophylaxis, post-exposure prophylaxis, and the treatment of exposure to viruses, bacteria and toxins. The meeting is scheduled to take place October 29-30, 2024, at the United States Patent and Trademark Office in Alexandria, VA -- The JPEO-CBRND manages U.S. government investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment and medical countermeasures (MCMs).
prnewswire.com
- 2 months ago
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely used in industrial processes for the manufacture of plastics and pesticides.
prnewswire.com
- 2 months ago
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV) -- The funding advances opaganib's positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV -- Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks -- This year marks the 10th anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO) 1 -- Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction.
prnewswire.com
- 3 months ago
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Medi-Cal, California's Medicaid healthcare program, and RedHill have renewed their contract to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization and a $0 copay – a major benefit for approximately fifteen million Californian Medi-Cal patients -- The renewed terms reflect both parties' ongoing commitment to improving patient access and outcomes, reinforcing Talicia's role as an essential treatment option, and follow the new American College of Gastroenterology (ACG) Clinical Guideline 1 for H. pylori infection, listing Talicia as an empirically prescribed first-line option -- Talicia's convenient all-in-one three-times daily (TID) formulation offers a simplified patient experience, supporting high rates of H.
prnewswire.com
- 3 months ago
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204 Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no longer requiring supplemental oxygen by day 14 of opaganib treatment (76.9% vs. 63.4%; p-value =0.033), a 62.6% reduction in intubation/mechanical ventilation (6.84% vs.
prnewswire.com
- 3 months ago
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
First new American College of Gastroenterology (ACG) Clinical Guideline [1] for H. pylori infection since Talicia's approval lists Talicia as an empirically prescribed first-line option Talicia's convenient all-in-one three times daily (TID) formulation offers a simplified patient experience, supporting high rates of eradication without needing prior resistance testing Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists [2] for H.
prnewswire.com
- 4 months ago
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
TEL AVIV, Israel and RALEIGH, N.C. , Sept. 5, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
prnewswire.com
- 4 months ago
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement in time to room air (no longer needing supplemental oxygen), has been newly published in the peer-reviewed journal, Microorganisms The analysis, from a large sub-group of 251 hospitalized, moderately severe COVID-19 patients requiring a fraction of inspired oxygen (FiO2) up to and including 60%, also indicates that FiO2 of greater than 60% may represent a threshold level for disease severity, and may potentially be a patient selection biomarker, an important finding for future therapeutic strategies and studies With 30,000 Americans dead due to COVID-19 so far this year according to the World health Organization[1], new, effective and safe therapies are still very much needed With multiple U.S. government collaborations ongoing, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles in oncology indications, viral infection, nuclear/radioprotection and other inflammatory diseases TEL AVIV, Israel and RALEIGH, N.C., Sept. 3, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
prnewswire.com
- 4 months ago
RedHill Biopharma Announces First Half 2024 Business Highlights
A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others : Executing on our plan to ensure a value-driven focus, operational efficiency and financial streamlining with a low cost-base U.S. government collaborations : Developing a promising, advancing and largely financially de-risked pipeline via U.S. government and other collaborations Addressing substantial and underserved indications : In oncology viral pandemic preparedness, nuclear/radioprotection, and obesity/diabetes Building value : In the lab and in the clinic through new studies, generating new intellectual property and publications and forging the right partnerships for our assets Streamlined U.S. commercial organization : Cost reduction measures resulted in a much smaller, more efficient and cost-effective organization while still maintaining a leadership position with Talicia ® R&D and Commercial Highlights : Opaganib: - U.S. Army program for Ebola (believed to be the first host-directed molecule to show activity in vivo in Ebola virus disease)- Orphan drug designation granted by FDA for neuroblastoma - Discussions ongoing for a potential externally-funded, mid-stage clinical study in an additional underserved oncology indication - U.S. government-funded programs ongoing with the NIH / BARDA-funded nuclear and chemical medical countermeasure programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure - Positive in vivo study results support potential of opaganib therapy in diabetes / obesity RHB-107: - COVID-19: Enrollment ongoing in the U.S Department of Defense-supported 300-patient Phase 2 ACESO PROTECT platform trial for early COVID-19 outpatient treatment; enrollment estimated to be completed in the first half of 2025 - U.S. Army-funded Ebola development program ongoing; RHB-107 also demonstrated robust synergistic effect in vitro when combined with remdesivir RHB-104 : Newly published positive Phase 3 data demonstrated 64% increased efficacy with RHB-104 in Crohn's disease Talicia: The leading prescribed branded H. pylori therapy in the U.S., maintaining leadership position with a streamlined commercial team: - Expected upcoming new H.
prnewswire.com
- 4 months ago
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pediatric cancer-related deaths [1], [2] Orphan Drug designation provides for seven-years' marketing exclusivity should opaganib be approved in neuroblastoma and may confer additional benefits such as accelerated development and review times, potential grant funding and possible tax credits The neuroblastoma market is expected to reach almost $1.5 billion before mid-2030s [3] This is the second orphan drug designation by the FDA for opaganib in oncology, after cholangiocarcinoma (bile duct cancer, CCA) With multiple U.S. government collaborations ongoing, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles TEL AVIV, Israel and RALEIGH, N.C.
prnewswire.com
- 4 months ago
8. Profile
Summary
RedHill Biopharma Ltd. RDHL
COUNTRY
IL
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 7.18 M
Dividend Yield
0.00%
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Contact
21 Ha’arba’a Street, Tel Aviv, 6473921
https://www.redhillbio.com
IPO
Date
Jan. 7, 2013
Employees
53
Officers
Mr. Rick D. Scruggs
Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
Mr. Gilead Raday MPhil, MSc
Chief Operating Officer
Mr. Guy Goldberg J.D.
Chief Business Officer
Mr. Dror Ben-Asher
Co-Founder, Chairman & Chief Executive Officer
Ms. Alexandra Okmian
Senior Business Development & Investor Relations Manager
Dr. Reza Fathi Ph.D.
Senior Vice President of Research & Development
Ms. Patricia Anderson B.Sc. RAC
Senior Vice President of Regulatory Affairs
Mr. Razi Ingber
Chief Financial Officer
Mr. Adi Frish
Chief Corporate & Business Development Officer